Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Desano Pharmaceuticals

- PMLiVE

GSK buys Novartis out of consumer health JV after ditching Pfizer bid

Will pay $13bn for the 36.5% stake owned by the Swiss drug maker

- PMLiVE

ViiV’s two-drug HIV combo backed by CHMP

The committee also backs two biosimilar medicines

- PMLiVE

GSK joins Reckitt in passing on Pfizer’s consumer health unit

The healthcare business doesn’t meet GSK’s criteria for returns, says Walmsley

- PMLiVE

Ex-GSK CEO Witty named head of pharmacy benefit firm Optum

Current Optum CEO Larry Renfro will move to Optum Ventures as MD

- PMLiVE

Theratechnologies’ last-ditch HIV drug approved by FDA

The injectable becomes an add-on treatment for patients who have previously taken ART

Gilead Sciences

Gilead says switching studies back new HIV therapy Biktarvy

Patients who switched from rival Triumeq could maintain viral suppression over the trial period

Gilead Sciences

Gilead study resurrects HIV eradication hope

Intends to start human trials of its improved bNAb candidate

- PMLiVE

A catalyst for change

China’s plan to boost innovation and improve drug accessibility

- PMLiVE

FDA hands GSK a reprieve by blocking Novartis generic

The Advair rival could be delayed until 2019

- PMLiVE

Gilead’s triple HIV drug approval prompts GSK lawsuit

ViiV claims bictegravir infringes its patent estate

AstraZeneca AZ

AZ’s COPD triple data sets up market clash with GSK

KRONOS trial showed significant improvements in lung function tests over two-drug combos

AstraZeneca AZ

AZ gets EMA green light for severe asthma drug Fasenra

The biologic respiratory treatment will go up against GSK’s Nucala and Teva’s Cinqaero

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links